Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 1860 • ACR Convergence 2025
GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
Bo Broens¹, Conny van der Laken¹, Teodora Radonic¹, Douwe Mulder², esther Nossent¹, Yehya Al-Adwi², Tji Gan², Wim Timens², Alexandre Voskuijl³ and Jan Willem Duitman¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²UMCG Groningen, Groningen, Netherlands, ³Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: The clinical management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is challenging due to its heterogeneous progression. While recent studies have shown that pulmonary…
Abstract Number: 1287 • ACR Convergence 2025
A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Ivan Foeldvari¹, Kathryn Torok², Ozgur Kasapcopur³, Amra Adrovic⁴, Flavio Sztajnbok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Raju Khubchandani⁹, Sindhu Johnson¹⁰, Gülcan Özomay Baykal¹¹, Brian Feldman¹², Dieneke Schonenberg-Meinema¹³, Sujata Sawhney¹⁴, Vanessa Smith¹⁵, Eslam Al-Abadi¹⁶, Simone Appenzeller¹⁷, Stefanie Hajek¹⁸, Maria Katsicas¹⁹, Mikhail Kostik²⁰, Suzanne Li²¹, Hana Malcova²², Anjali Patwardhan²³, Walter Alberto Sifuentes-Giraldo²⁴, Natalia Vasquez-Canizares²⁵, Tadej Avcin²⁶, Patricia Costa Reis²⁷, Siri Opsahl Hetlevik²⁸, Mahesh Janarthanan²⁹, Edoardo Marrani³⁰, Clare Pain³¹, Maria Jose Santos³², Valda Stanevica³³, Sima Abu Alsaoud³⁴, Ekaterina Alexeeva³⁵, Cristina Battagliotti³⁶, Lillemor Berntson³⁷, blanca e r bica³⁸, Jürgen Brunner³⁹, Despina Eleftheriou⁴⁰, Liora Harel⁴¹, Tilmann Kallinich⁴², Dragana Lazarevic⁴³, Kirsten Minden⁴⁴, Dana Nemcova⁴⁵, Susan Nielsen⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸, Yosef Uziel⁴⁹ and Nicola Helmus⁵⁰, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Turkey, Turkey, ⁵UFRJ/UERJ, SAO PAULO, Brazil, ⁶UNIFESP, São Paulo, São Paulo, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil, ⁸Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Jaslok Hospital and Research Center, Mumbai, India, ¹⁰Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Umraniye Training and Research Hospital, Istanbul, Turkey, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁴Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷Unicamp, Campinas, São Paulo, Brazil, ¹⁸Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ¹⁹Hospital Garrahan, Buenos Aires, Argentina, ²⁰Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²¹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ²²Motol University Hospital, Prague, Czech Republic, ²³University of Missouri-Columbia, Columbia, MO, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Children’s Hospital at Montefiore, Bronx, NY, ²⁶University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²⁷Hospital de Santa Maria, Lisbon, Portugal, ²⁸Oslo University Hospital, Oslo, Norway, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁰Meyer Children Hospital IRCCS, Firenze, Italy, ³¹Alder Hey NHS Trust, Liverpool, United Kingdom, ³²Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ³⁴Caritas baby Hospital, Jerusalem, Palestine, ³⁵National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ³⁶Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁷Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁸UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ³⁹Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴⁰Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴¹Schneider Children's Medical center, Nettnja, Israel, ⁴²Charite University Medicine Berlin, Berlin, Germany, ⁴³Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁴German Rheumatism Research Center, Berlin, Germany, ⁴⁵Charles University, Prague, Czech Republic, ⁴⁶Rigshospitalet, Copenhagen, Denmark, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, ⁴⁹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁵⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult systemic sclerosis is interstitial lung…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 1855 • ACR Convergence 2025
Small Bowel Microbial Dysbiosis and Impaired Intestinal Absorptive Function in Systemic Sclerosis- A Single Center Prospective Study
Adam Edwinson¹, Elvira Lesmana², Thomas Guedens³, Ruben Mars³, Margaret Breen-Lyles⁴, Stephen Johnson³, Jun Chen³, Madhusudan Grover⁴ and Ashima Makol¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, USA, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Systemic sclerosis (SSc) is characterized by peripheral vasculopathy and widespread fibrosis of skin and internal organs. Up to 90% of SSc patients report gastrointestinal…
Abstract Number: 1288 • ACR Convergence 2025
Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Ivan Foeldvari¹, Kathryn Torok², Ozgur Kasapcopur³, Amra Adrovic⁴, Brian Feldman⁵, Flavio Sztajnbok⁶, Maria Teresa Terreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Sindhu Johnson¹⁰, Raju Khubchandani¹¹, Valda Stanevica¹², Gülcan Özomay Baykal¹³, Dieneke Schonenberg-Meinema¹⁴, Eslam Al-Abadi¹⁵, Ekaterina Alexeeva¹⁶, Maria Katsicas¹⁷, Sujata Sawhney¹⁸, Vanessa Smith¹⁹, Sima Abu Alsaoud²⁰, Simone Appenzeller²¹, Tadej Avcin²², Natalia Cabrera²³, Stefanie Hajek²⁴, Siri Opsahl Hetlevik²⁵, Mikhail Kostik²⁶, Thomas Lehman²⁷, Suzanne Li²⁸, Hana Malcova²⁹, Edoardo Marrani³⁰, Clare Pain³¹, Anjali Patwardhan³², Walter Alberto Sifuentes-Giraldo³³, Natalia Vasquez-Canizares³⁴, Patricia Costa Reis³⁵, Mahesh Janarthanan³⁶, Maria Jose Santos³⁷, Cristina Battagliotti³⁸, Lillemor Berntson³⁹, blanca e r bica⁴⁰, Jürgen Brunner⁴¹, Liora Harel⁴², Gerd Horneff⁴³, Daniela Kaiser⁴⁴, Jorge Lopez-Benitez⁴⁵, Farzana Nuruzzaman⁴⁶, Mihaela Sparchez⁴⁷, Yosef Uziel⁴⁸ and Nicola Helmus⁴⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Turkey, Turkey, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶UFRJ/UERJ, SAO PAULO, Brazil, ⁷UNIFESP, São Paulo, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil, ⁹Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ¹⁰Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Jaslok Hospital and Research Center, Mumbai, India, ¹²Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³Umraniye Training and Research Hospital, Istanbul, Turkey, ¹⁴Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁶National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ¹⁷Hospital Garrahan, Buenos Aires, Argentina, ¹⁸Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Caritas baby Hospital, Jerusalem, Palestine, ²¹Unicamp, Campinas, São Paulo, Brazil, ²²University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²³IPS Central: Asunción, Asuncion, Paraguay, ²⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ²⁵Oslo University Hospital, Oslo, Norway, ²⁶Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁷Hospital for Special Surgery, New York, ²⁸Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ²⁹Motol University Hospital, Prague, Czech Republic, ³⁰Meyer Children Hospital IRCCS, Firenze, Italy, ³¹Alder Hey NHS Trust, Liverpool, United Kingdom, ³²University of Missouri-Columbia, Columbia, MO, ³³Hospital Universitario Ramón y Cajal, Madrid, Spain, ³⁴Children’s Hospital at Montefiore, Bronx, NY, ³⁵Hospital de Santa Maria, Lisbon, Portugal, ³⁶SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁷Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³⁸Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁴⁰UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ⁴¹Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴²Schneider Children's Medical center, Nettnja, Israel, ⁴³Asklepios Klinik, Hamburg, Germany, ⁴⁴Childrens Hospital Lucerne, Lucerne, Switzerland, ⁴⁵Private Practice, Asuncion, Paraguay, ⁴⁶Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁷Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, ⁴⁸Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁴⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Gastroesophageal involvement, particularly reflux, has been identified as a risk factor for development and progression of interstitial lung disease (ILD) in adult systemic sclerosis…
Abstract Number: 0823 • ACR Convergence 2025
Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes
Julia Elrod¹, Theresa hutchins², Anwesha Sanyal², Paul Szabolcs², Paulina Horvei², Jon Li², F. William Townes¹ and Kathryn Torok², ¹Carnegie Mellon, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare, life-threatening autoimmune disease characterized by fibrosis and immune dysregulation. Autologous stem cell transplant (ASCT) is an emerging…
Abstract Number: 1590 • ACR Convergence 2025
Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
Yuzo Ikari¹, Poulami Dey², James St. Clair³, Anna Webber⁴, Caroline Foster⁵, Yi-Chen Chen⁵, Ramadan Ali⁶, Dinesh Khanna⁷, David Fox⁸ and Pei-Suen Tsou⁷, ¹Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁶University of Michigan, Ann Arobr, MI, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Michigan, Dexter, MI
Background/Purpose: Soluble CD13 (sCD13), released by the cleavage of cell surface CD13 by matrix metalloproteinase-14 (MMP14), has potent proinflammatory, angiogenic, and arthritogenic activities. The receptors…
Abstract Number: 0977 • ACR Convergence 2025
The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis
Lichong Shen¹, Xianyi Meng², Yun Zhang³ and Joerg Distler⁴, ¹³Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, Germany, ³University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, Germany
Background/Purpose: Nuclear receptors are a family of transcription factors that is commonly targeted for therapeutic intervention. Dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on…
Abstract Number: 0812 • ACR Convergence 2025
Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis
Chanhyuk Park¹, Helen Jarnagin², Asmaa Mohamed³, Noelle Kosarek⁴, Owen Wilkins¹, Fred Kolling¹, Yina Huang¹, Michael Whitfield⁵ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Charlottesville, VA, ⁴Dartmouth Geisel School of Medicine, Lebanon, NH, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a progressive, chronic multi-system disorder of unknown etiology that is characterized by immune dysfunction, fibrosis, and loss of dermal white…
Abstract Number: 2655 • ACR Convergence 2025
Fetal and maternal outcomes in systemic sclerosis and very early diagnosis of systemic sclerosis pregnancies, a national prospective study
Anne Murarasu¹, lauren beaudeau², Véronique Le Guern³, gaelle guettrot-Imbert³, claire cazalets⁴, cecile durant⁵, Cecile Yelnik⁶, Céline Roussin⁷, Marie-Charlotte Besse⁸, Emilie Berthoux⁹, Emmanuel Chatelus¹⁰, Eric Hachulla¹¹, Estibaliz LAZARO¹², Francois Maurier¹³, Gaelle leroux¹⁴, Grégory Pugnet¹⁵, Isabelle durieu¹⁶, Loic RAFFRAY¹⁷, Maelle Le Besnerais¹⁸, Mélanie roriz¹⁹, Odile SOUCHAUD-DEBOUVERIE²⁰, Patrick JEGO²¹, Pauline ORQUEVAUX²², Claire de Moreuil²³, Helene MAILLARD²⁴, Nathalie Morel²⁵, Anna Molto²⁶, Camille Le Ray²⁷, emmanuelle pannier²⁷, loic sentilhes²⁵, Luc Mouthon²⁸, Nathalie Costedoat-Chalumeau²⁹ and Benjamin Chaigne³⁰, ¹Tours University Hospital, Tours, France, ²Centre Hospitalier Ales Les Cevennes, Ales, France, ³Cochin hospital, Paris, France, ⁴Rennes Hospital, Rennes, France, ⁵Nantes University Hospital, Nantes, France, ⁶lille university, Lille, France, ⁷Centre Hospitalier Ouest Réunion, Saint Paul, France, ⁸Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ⁹Internal Medicine, Saint Luc Saint Joseph Hospital, Lyon, France, ¹⁰Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹¹University of Lille, LILLE, France, ¹²Bordeaux University Hospital, Pessac, France, ¹³HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ¹⁴Pitié-Salpêtrière University Hospital, Paris, France, ¹⁵CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹⁶Lyon University Hospital, Lyon, France, ¹⁷Félix-Guyon University Hospital of La Réunion, Saint Denis, France, ¹⁸Rouen University Hospital, Rouen, France, ¹⁹Agen hospital, Agen, France, ²⁰Poitiers University Hospital, Poitiers, France, ²¹Rennes University Hospital, Rennes, France, ²²Reims University Hospital, Reims, France, ²³CHU DE BREST, BREST, France, ²⁴Lille University Hospital, Lille, France, ²⁵Bordeaux University Hospital, Bordeaux, France, ²⁶Assistance Publique Hôpitauxde Paris, Paris, France, ²⁷Cochin Port Royal University Hospital, Paris, France, ²⁸Hopital Cochin - Paris University, Paris, France, ²⁹Inserm DR Paris ⁵, Paris, France, ³⁰Cochin University Hospital, Paris, France
Background/Purpose: Pregnancy in women with systemic sclerosis (SSc) is considered high-risk due to complications like scleroderma renal crisis and preeclampsia, related to vasculopathy. Prospective data…
Abstract Number: 1589 • ACR Convergence 2025
Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
Punchalee Kaenmuang¹, Nina Goldman², Arthihai Srirangan¹, Fiammetta Danzo¹, Wing-Ho Yip¹, Ali Taki³, Shereen Boreland¹, Benedetta Vitri¹, Carmel JW. Stock¹, Christopher Denton⁴, Athol U. Wells¹, Voon H. Ong⁵, Piersante Sestini⁶ and Elisabetta A. Renzoni¹, ¹Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy’s and St Thomas’ National Health Service Foundation Trust, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Royal Free Hospital, London, England, United Kingdom, ⁴University College London, UK, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁶Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Toscana, Italy
Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…
Abstract Number: 0976 • ACR Convergence 2025
LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Yuan Zhan¹, Colton Sanders², Michael Diaz², Jinmin Miao³, Arminja Kettenbach⁴, Zhong-Yin Zhang⁵, Paul Wolters⁶, Francesco Boin⁷, Stephanie Stanford² and Nunzio Bottini⁸, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³Purdue University, West Lafayette, IN, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, ⁶University of California San Francisco, San Francisco, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The identification of effective and safe anti-fibrotic agents is a critical unmet need in systemic sclerosis (SSc). Although fibrosis in SSc is driven by…
Abstract Number: 0811 • ACR Convergence 2025
SSc Skin Cell Atlas: a Scalable Web Portal for scRNA-Seq Analysis
Helen Jarnagin¹, Zhiyun Gong¹, Rachael Bogle², Alex Tsoi², Rezvan Parvizi³, Madeline Morrisson⁴, Dinesh Khanna⁵, Johann Gudjonsson⁵ and Michael Whitfield⁶, ¹Dartmouth College, Lebanon, NH, ²University of Michigan, Holland, OH, ³Dartmouth, lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵University of Michigan, Ann Arbor, MI, ⁶Geisel School of Medicine, Lebanon, NH
Background/Purpose: Despite the recent popularity and utility of modern high-resolution sequencing technologies, leveraging publicly available single-cell studies remains hampered by the need for substantial computational…
Abstract Number: 2653 • ACR Convergence 2025
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Ana Paula Luppino-Assad¹, Renata P Mello², Ana C Medeiros-Ribeiro³, Nadia E Aikawa⁴, Sandra G Pasoto³, Leonard V Kupa⁵, Renata Miossi⁶, Percival D Sampaio-Barros⁶, Eduardo Borba⁷, Eloisa Bonfa⁷ and Clovis Artur Silva⁸, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ⁷Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Systemic sclerosis (SSc) patients are at higher risk of herpes zoster (HZ) due to underlying immune dysregulation and immunosuppressive therapies. Vaccination is a key…
Abstract Number: 1587 • ACR Convergence 2025
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Stefano Di Donato¹, JUAN JOSE ALEGRE SANCHO², Anastas Batalov³, Zguro Batalov⁴, Silvia Bellando-Randone⁵, carmela coccia⁶, Marco de Pinto⁷, Dilia Giuggioli⁸ and Michael Hughes⁹, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Medical University of Plovdiv, Plovdiv, Bulgaria, ⁴UMHAT Kaspela, Ploudiv, Bulgaria, ⁵University of Florence, Florence, Florence, Italy, ⁶Rheumatology Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy, ⁷Azienda Ospedaliero Universitaria Policlinico di Modena, Parma, Parma, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: JAK inhibitors (JAKi) have shown promising early results in systemic sclerosis (SSc) patients, yet real-world data on their longitudinal effects across different disease domains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].